Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

This is because the drugs may be expelled from the body before they have an opportunity to be absorbed into the blood stream.

McDonald’s faces falling visits and shrinking demand as GLP-1 drugs and price fatigue reshape consumer habits.

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its 2025-26 budget plans.

A Slimming World group leader from Lowestoft has given some advice amid the rise of weight loss injections such as Mounjaro, Ozempic and Wegovy.